Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
about
Insights into CYP2B6-mediated drug-drug interactionsAdverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medicationAntiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.Liver autophagy in anorexia nervosa and acute liver injuryEffect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin cityThe effect of aging, nutrition, and exercise during HIV infection.Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children.Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South AfricaHIV-related liver disease: ARV drugs, coinfection, and other risk factors.Differential gene expression in HIV-infected individuals following ART.HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.Causes of liver disease and its outcome in HIV-infected individuals.Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.Evaluation of Adverse Drug Reaction Profile of Drugs Used as First-Line Antiretroviral Therapy
P2860
Q28078857-661EE23D-D20D-48B2-8282-37368310ADFCQ28749406-E71B1027-E556-432B-80C8-FBCFCA8F1AA7Q31050092-892FD4E1-D759-43F5-977D-08609BDE30B6Q34177327-12AE6645-0F89-4D8B-AA2E-6AD4083DA8AEQ34443184-05FA3FD7-38AD-4579-B721-B6FED3664855Q34536677-1E1679AE-75C1-46F2-B8BA-58F637300218Q34794696-C0E963F6-EB56-4044-A6EE-77FD799CBA94Q35364120-937F2770-AE2F-4770-BD7C-ABBD62BECE54Q35542957-B32C4544-4011-47AC-AB33-C9919B049B7AQ35557264-2E79F877-A7E9-4BE3-9CD8-1475F168D87FQ35619539-D1C4568A-66CC-4A30-86D6-C831340F9173Q35692270-74D64BC4-6178-4963-8BC5-4CC83957C44FQ36074119-9D446922-358C-4703-A3B5-71369CDA0804Q36286145-1A490AC3-4890-47E4-8D1E-36953104F3F1Q36922243-17D9E04C-B632-4445-9EA0-BC54B02C66ADQ37330398-0AD14F69-D81D-419D-909E-675ABF178BF5Q37391122-A961394D-A05B-4DDC-8C6F-A0F36A989F72Q37507953-DAF73F3D-E9F7-461B-8F1E-3274703D9A43Q37644125-94D548E7-5832-40C8-81FA-0A32836CE7FDQ37784777-FD61B71F-D9AA-452B-9821-AF59EA51961BQ38111430-88A2EE12-A5CE-41ED-872F-C3414923A885Q38554604-9A8AAEE5-87FD-4BCF-8B55-CC9F1796FFB5Q38916843-A50F2DC8-2AF0-4759-A896-D497C38A247CQ40607367-69E7B91F-0BAC-4394-94D7-BCBA8011CDDFQ40784890-2834406B-341E-4E3B-8167-73C209FCA1ECQ43040351-9C70C797-2872-4057-BF78-1BDF11C496D5Q50552164-A21D70E6-FBEC-4955-9A48-CAF680440D49Q58803006-2DC226C6-2553-4688-A92D-192CD98DE465
P2860
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
@ast
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
@en
type
label
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
@ast
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
@en
prefLabel
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
@ast
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
@en
P2860
P356
P1476
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors
@en
P2093
José A Mira
P2860
P304
P356
10.1093/JAC/DKL524
P407
P577
2007-01-25T00:00:00Z